Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 84,88
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 212 pages. 9.00x6.00x9.00 inches. In Stock.
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
EUR 153,70
Anzahl: 1 verfügbar
In den WarenkorbPAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 164,60
Anzahl: 1 verfügbar
In den WarenkorbZustand: New. In.
EUR 130,16
Anzahl: 1 verfügbar
In den WarenkorbZustand: NEW.
Zustand: New. Presents an examination of contraceptive development in the United States, covering research, funding, regulation, product liability, and the effect of public opinion. This book provides a blueprint for substantial change, with specific policy recommendatio.
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Presents an examination of contraceptive development in the United States, covering research, funding, regulation, product liability, and the effect of public opinion. This book provides a blueprint for substantial change, with specific policy recommendations that promise to gain the attention of specialists, the media, and the American public. Num Pages: 212 pages. BIC Classification: KNDP; MBNH4. Category: (P) Professional & Vocational. Dimension: 229 x 152. . . 1990. Revised ed. paperback. . . . . Books ship from the US and Ireland.
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Developing New Contraceptives | Obstacles and Opportunities | Commission on Behavioral and Social Sciences and Education (u. a.) | Taschenbuch | Kartoniert / Broschiert | Englisch | 1990 | National Academies Press | EAN 9780309083522 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu.
Sprache: Englisch
Verlag: National Academies Press Feb 1990, 1990
ISBN 10: 0309083524 ISBN 13: 9780309083522
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Neuware - There are numerous reasons to hasten the introduction of new and improved contraceptives--from health concerns about the pill to the continuing medical liability crisis. Yet, U.S. organizations are far from taking a leadership position in funding, researching, and introducing new contraceptives--in fact, the United States lags behind Europe and even some developing countries in this field. Why is research and development of contraceptives stagnating What must the nation do to energize this critical arena.